RTW Investments ARVN Position
Exited8-Fund ConvergenceRTW Investments exited their position in Arvinas Inc. (ARVN) in Q2 2025, after holding the stock for 7 quarters.
The position was first reported in Q4 2023 and has been tracked across 7 quarterly 13F filings.
ARVN is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ARV-806 in 593 days (Nov 30, 2027), making the timing of RTW Investments's position particularly relevant.
About Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Full company profile →Short Interest
7.6%
5.6 days to cover
RTW Investments ARVN Position History
Frequently Asked Questions
Does RTW Investments own ARVN?
No. RTW Investments exited their position in Arvinas Inc. (ARVN) in Q2 2025. They previously held the stock for 7 quarters.
How many hedge funds own ARVN?
8 specialist biotech hedge funds currently hold ARVN, including EcoR1 Capital, Commodore Capital, Perceptive Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RTW Investments first buy ARVN?
RTW Investments's position in ARVN was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RTW Investments's ARVN position increasing or decreasing?
RTW Investments completely exited their ARVN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ARVNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RTW InvestmentsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →